Which patients this injection is usually suited for

Not every patient with knee or hip cartilage damage will be suitable for a ChondroFiller injection — and understanding why that is helps set realistic expectations before booking a consultation.

The treatment is designed for what clinicians describe as a focal defect: a contained area of cartilage loss, typically graded III or IV on standard clinical scoring, in an otherwise reasonably preserved joint. Think of it as a pothole in an otherwise usable road surface, rather than widespread crumbling across the whole carriageway. That distinction matters because patients with diffuse, end-stage osteoarthritis — where degeneration affects the joint broadly rather than in a discrete zone — fall outside the primary injectable indication. For those patients, other pathways are likely more appropriate.

MRI imaging is needed to confirm whether a defect is focal and to determine its size before any treatment decision can be made responsibly.

One misconception worth addressing: there is no stated upper age limit for the injectable pathway. Patients in their sixties or older who assume they are automatically excluded should discuss their imaging and joint health with a specialist, since age alone does not determine suitability. A formal clinical assessment remains the only reliable way to confirm whether ChondroFiller is the right approach for any individual.

How the injectable collagen scaffold works

Understanding the mechanism helps explain why ChondroFiller sits in a distinct clinical category — and why not every injection clinic can deliver it.

The product arrives as a liquid held in a dual-chamber syringe. Once introduced into the joint under real-time ultrasound guidance during an outpatient appointment, the two components combine and self-polymerise, conforming to the shape of the cartilage defect and setting into a dimensionally stable hydrogel scaffold within approximately three to five minutes. No incision is made; the procedure is completed in a clinic setting without general anaesthetic.

What follows is a process called matrix-induced chondrogenesis. Rather than introducing external cells, the scaffold acts as a structural framework that recruits the patient's own progenitor cells — drawn from the surrounding synovium and subchondral bone — to colonise and work within it. In this way, ChondroFiller supports the body's own repair processes through acellular matrix-induced chondrogenesis, rather than replacing tissue directly.

As a CE-marked Class III medical device — the highest risk tier under European medical device regulation — it carries requirements for specialist ordering, careful handling, and image-guided placement that go beyond what a general injection service can provide.

This mechanism is fundamentally different from viscosupplementation (hyaluronic acid) or corticosteroid, both of which address symptoms without providing a structural scaffold. ChondroFiller's clinical goal is tissue support and endogenous repair, not lubrication or inflammation control.

Qualified UK specialists and how to find one

Because ChondroFiller is a CE-marked Class III device requiring specialist ordering protocols, prior MRI review, and real-time ultrasound guidance during the injection itself, it is not available through general injection clinics or GP-led services. The infrastructure requirements are specific, and the number of UK clinicians currently trained and equipped to offer it remains relatively small.

Geographically, provision is concentrated rather than evenly distributed: documented treatment locations currently include London, the East Midlands, and Scotland. Patients based elsewhere should factor in travel from the outset, or consider beginning with a remote clinical assessment to establish suitability before committing to a journey.

No GP referral is needed. Many patients assume that self-referral is not possible for a specialist treatment of this kind — it is. Patients can contact qualified clinics directly and arrange a suitability screen without waiting for a letter from their GP, which removes a common and avoidable delay in the early stages of the pathway.

When evaluating whether a specific clinic is genuinely set up to deliver ChondroFiller, two practical markers stand out. First, the clinic must be able to review MRI imaging before any treatment decision is made — defect size, location, and surrounding tissue condition all need to be visible before box count or suitability can responsibly be confirmed. Second, the treating clinician must have real-time ultrasound guidance available for the injection itself. A clinic that offers a cost estimate before seeing any imaging is, at minimum, quoting without the clinical information needed to do so accurately.

A directory of UK specialists offering ChondroFiller injection, searchable by region and specialty, is available through Search MSK.

What the assessment process and appointment involve

Once you have identified a suitably equipped specialist, the pathway to treatment follows a clear sequence.

MRI imaging first. Before any clinical decision is possible, you will need an MRI of the affected joint. This is not a formality — the scan reveals defect size, location, and the condition of the surrounding tissue, all of which determine whether ChondroFiller is appropriate and, if so, how many boxes of product will be required. Attending a consultation without up-to-date imaging simply delays that decision.

Suitability screening. Many clinics offer an initial screen — sometimes an online questionnaire, sometimes a short remote call — before a paid consultation is booked. This can save time for patients who may not yet meet the basic clinical criteria.

Consultation and treatment planning. At your consultation, the imaging is reviewed, box count is confirmed, and a personalised treatment plan is agreed. No two defects are identical, so this step cannot responsibly be skipped.

The injection appointment. The procedure itself is an outpatient appointment. There is no general anaesthetic, no theatre admission, and no surgical incision. The product is placed under real-time ultrasound guidance during your clinic visit.

Six-week follow-up. A follow-up appointment at around six weeks is standard practice, allowing early response to be assessed and any questions addressed.

Costs, funding, and what the price typically covers

ChondroFiller is not available on the NHS and is not currently covered by major UK private medical insurers such as Bupa or AXA. Every element of the cost falls to the patient as self-funded private care — worth confirming at the outset rather than discovering mid-pathway.

Guide costs vary according to how many boxes of product the defect requires. UK providers publish ranges from roughly £2,000–£3,000 for a single-box treatment up to approximately £8,000 where three boxes are needed for a larger or multi-compartment defect. Most patients are treated with one or two boxes, but the exact number — and therefore the total guide cost — can only be confirmed once imaging has been reviewed.

Inclusive pricing at specialist clinics typically covers the initial consultation, imaging review, the product itself, ultrasound guidance during the injection, and a follow-up appointment at around six weeks. Some clinics quote a lower headline figure that excludes one or more of those components. Asking for a written breakdown of what is and is not included is a practical step before comparing costs across providers — what looks like a cheaper quote may simply be a less complete one.

What the outcome evidence currently shows

The published safety record across more than 19,000 cases treated worldwide is notable: a reported complication rate of approximately 0.06% places ChondroFiller among the better-tolerated injectable therapies in regenerative orthopaedics.

Functional outcomes in published series are measured using validated scoring tools. The IKDC score captures knee pain, function, and activity level on a 0–100 scale; treated patients have shown an improvement of around 30 points at 12–36 months — a change large enough to be clinically meaningful in everyday terms. Hip outcomes are tracked using the Harris Hip Score, where published data show an improvement of approximately 33 points over the same follow-up window. MOCART scoring, which uses follow-up MRI to assess how thoroughly a cartilage defect has been filled with repair tissue, has returned results in the 70–87 range — indicating consistent scaffold integration across reported cases. Across knee, hip, and small-joint applications, around 70–85% of patients in available studies achieve meaningful symptom relief that persists to 3–5 years.

An honest note on the evidence base

Most of the data underpinning these figures come from manufacturer-sponsored cohort studies rather than independent randomised controlled trials. That does not invalidate the findings, but it is a limitation patients should factor into their expectations. Independent UK patient registries are not yet publicly available.

Individual results will also vary considerably — defect size, joint condition, activity level, and patient-specific factors all influence what a realistic outcome looks like. A specialist assessment, informed by current imaging, is the only reliable way to gauge likely suitability.